A therapeutic role for cyclooxygenase‐2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Recent studies indicate that the proinflammatory enzyme cyclooxygenase (COX)‐2, an enzyme involved in inflammatory cascades but also normal neuronal activities, is elevated in the brain and spinal cord of amyotrophic lateral sclerosis (ALS) patients and ALS mouse model systems. On the basis of this evidence, we explored the impact of COX‐2 inhibition on the onset and progression of ALS‐like disease in the G93A human superoxide dismutase (SOD)1 mouse model of ALS. We found that prophylactic administration of nimesulide, a preferential COX‐2 inhibitor, in the feed resulted in a significant delay in the onset of ALS type motor impairment. This delay of ALS symptomatology temporally overlapped with the inhibition of prostaglandin E 2 elevation in the spinal cord of SOD1‐G93A transgenic mice relative to untreated SOD1‐G93A controls. This study strongly supports a role for COX‐2 in the pathophysiology of ALS and provides the first experimental evidence that prophylactic treatment with COX‐2 inhibitors can significantly delay the onset of motor dysfunction in the SOD1‐G93A transgenic mouse model of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Cited by
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I. P., Naylor, A., Bountra, C., Banati, R. R., & Anand, P. (2006) · BMC Neurology · doi:10.1186/1471-2377-6-12 · Cited by 509
Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS
TURNER, B., & TALBOT, K. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.001 · Cited by 496
Di Giorgio, F. P., Boulting, G. L., Bobrowicz, S., & Eggan, K. C. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.09.017 · Cited by 485
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
“In addition, pioglitazone treated-SOD1-G93A mice showed decreased pro-inflammatory gene expression, and a simultaneous upregulation of anti-inflammatory gene expression, which ultimately delayed the overall progression of ALS (88).”
BackgroundNeuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease
Tracey, T. J., Steyn, F. J., Wolvetang, E. J., & Ngo, S. T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00010 · Cited by 433
Neuroprotective Function of the PGE2EP2 Receptor in Cerebral Ischemia
McCullough, L., Wu, L., Haughey, N., Liang, X., Hand, T., Wang, Q., Breyer, R. M., & Andreasson, K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4485-03.2004 · Cited by 361
Lost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
Neuroglia in neurodegeneration
Heneka, M. T., Rodríguez, J. J., & Verkhratsky, A. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.11.004 · Cited by 301
Trial of celecoxib in amyotrophic lateral sclerosis
Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Zhang, H., Andreasson, K. I., Rothstein, J. D., Drachman, D. B., & Northeast ALS Consortium (2006) · Annals of Neurology · doi:10.1002/ana.20903 · Cited by 301
A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis
Zhao, Z., Lange, D. J., Voustianiouk, A., MacGrogan, D., Ho, L., Suh, J., Humala, N., Thiyagarajan, M., Wang, J., & Pasinetti, G. M. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-29 · Cited by 286
Self-citationReduced oxidative damage in ALS by high‐dose enteral melatonin treatment
Weishaupt, J. H., Bartels, C., Pölking, E., Dietrich, J., Rohde, G., Poeggeler, B., Mertens, N., Sperling, S., Bohn, M., Hüther, G., et al. (2006) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00377.x · Cited by 282
The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches
Geloso, M. C., Corvino, V., Marchese, E., Serrano, A., Michetti, F., & D’Ambrosi, N. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00242 · Cited by 242
Schütz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G. E., Schürmann, B., Zimmer, A., & Heneka, M. T. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2038-05.2005 · Cited by 225
“, 2002 ; Pompl et al .”
MethodMicroglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis
Sargsyan, S. A., Monk, P. N., & Shaw, P. J. (2005) · Glia · doi:10.1002/glia.20210 · Cited by 203
“Pretreatment of hmSOD1 G93A transgenic mice with nimesulide, a COX-2 enzyme inhibitor, delayed the onset of motor neuron loss (Pompl et al., 2003).”
BackgroundNeuroprotective agents for clinical trials in ALS: A systematic assessment
Traynor, B. J., Bruijn, L., Conwit, R., Beal, F., O’Neill, G., Fagan, S. C., & Cudkowicz, M. E. (2006) · Neurology · doi:10.1212/01.wnl.0000223353.34006.54 · Cited by 193
Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis
Rao, S. D., & Weiss, J. H. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2003.11.001 · Cited by 168
Prostaglandin D2 mediates neuronal protection via the DP1 receptor
Liang, X., Wu, L., Hand, T., & Andreasson, K. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02870.x · Cited by 159
Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Béland, L.-C., Markovinovic, A., Jakovac, H., De Marchi, F., Bilic, E., Mazzini, L., Kriz, J., & Munitic, I. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa124 · Cited by 125
Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93
Blais, V., Turrin, N. P., & Rivest, S. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03480.x · Cited by 72
Status of ALS treatment, insights into therapeutic challenges and dilemmas
Khamaysa, M., & Pradat, P.-F. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101601 · Cited by 28
Chang, M. C., Kwak, S. G., Park, J.-S., & Park, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-71813-1 · Cited by 17
Metadata
- Authors
- Pompl, P. N., Ho, L., Bianchi, M., McManus, T., Qin, W., & Pasinetti, G. M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2003-02-05
- Volume
- 17
- Issue
- 6
- Pages
- 725-727
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2115637560
- Cited by
- 144
- References
- 2
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.